Filter Results
:
(1)
Show Results For
-
All HBS Web
(1)
- Faculty Publications (1)
Show Results For
-
All HBS Web
(1)
- Faculty Publications (1)
Symlin →
Page 1 of
1
Result
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a...
View Details
Keywords:
Regulations;
Drug Regulations;
Symlin;
Negotiation;
Governing Rules, Regulations, and Reforms;
Resource Allocation;
Negotiation Deal;
Product Development;
Research and Development;
Commercialization;
Pharmaceutical Industry;
United States
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)